Abbott in the news

Abbott introduces a blood-based colorectal cancer screening test for adults 45 and older at average risk.

Allina Health plans to establish a 90-bed inpatient hospital in Plymouth by relocating unused beds from Abbott Northwestern Hospital.

Abbott commercially launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening in the U.S. for average-risk adults aged 45 and older.

Abbott Laboratories agreed to a nearly $385 million settlement with federal and state governments over allegations of manufacturing non-compliant infant formula and nutritional products at its Arizona and Michigan plants.

Abbott settled for $385 million over contaminated baby formula allegations, with Mississippi receiving over $771,000.

The Big Ten Conference and Abbott are organizing a blood drive for the third year, urging college football fans to donate blood.

Gilead and Abbott are healthcare dividend stocks with contrasting growth drivers, Gilead focusing on HIV and Abbott on diversified medical devices and diagnostics.

Abbott Laboratories settled Medicaid fraud allegations for $384 million after knowingly selling contaminated baby formula, leading to a 2022 shortage and difficulties for parents.

Oregon will receive nearly $1 million from a $384 million settlement with Abbott Laboratories over allegations of selling taxpayer-funded baby formula produced under unsafe conditions.

Abbott is paying $385 million to resolve claims stemming from contamination issues and subsequent recalls at its Michigan baby formula factory, which caused supply shortages in 2022.

Abbott will pay Connecticut nearly $1 million as part of a larger $385 million settlement concerning allegations of manufacturing contaminated infant formula and withholding information.

Abbott will pay $385 million to settle claims from contamination and recall at its Sturgis baby formula plant, which caused 2022 supply shortages.

Abbott Laboratories settled for over $384 million regarding allegations of knowingly manufacturing and selling contaminated infant formula to federal and state programs.

Abbott will pay $385 million to settle lawsuits related to a 2022 baby formula contamination recall, despite company claims of no fault or liability and negative test results for bacteria in distributed products.

Abbott obtained a preliminary injunction in Milan against SiBio over a glucose-monitoring patent, blocking SiBio's product distribution in the UPC jurisdiction.

Abbott secured FDA approval for its TactiFlex Duo catheter, integrating pulsed field and radiofrequency ablation for atrial fibrillation treatment, aiming to boost its electrophysiology market share.

Abbott received FDA approval for its TactiFlex Duo ablation catheter, which combines pulsed-field ablation and radiofrequency energy to treat complex atrial fibrillation cases.

Abbott received FDA approval for its TactiFlex Duo Ablation Catheter, a device capable of both pulsed field ablation and radiofrequency energy to treat abnormal heart rhythms.

Abbott obtained FDA approval for its TactiFlex Duo, a dual-energy ablation catheter designed to treat complex atrial fibrillation by combining pulsed-field and radiofrequency energy.

Abbott's TactiFlex Duo dual-energy catheter shows one-year safety and effectiveness for atrial fibrillation treatment, supporting its FDA submission for U.S. market entry.